Livia Pasquali
Overview
Explore the profile of Livia Pasquali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filippi M, Pagani E, Turrini R, Bartezaghi M, Morra V, Borriello G, et al.
J Neurol
. 2024 Jul;
271(9):6181-6196.
PMID: 39073436
Background And Objectives: In multiple sclerosis (MS), MRI markers can measure the potential neuroprotective effects of fingolimod beyond its anti-inflammatory activity. In this study we aimed to comprehensively explore, in...
2.
Signoriello E, Signori A, Lus G, Romano G, Marfia G, Landi D, et al.
Mult Scler Relat Disord
. 2024 May;
87:105594.
PMID: 38718748
Background: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in...
3.
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, et al.
Eur J Neurol
. 2024 Mar;
31(6):e16250.
PMID: 38549186
Background And Purpose: Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment...
4.
Giovannini B, Panelli D, Bianchi F, Siciliano G, Pasquali L
Neurol Sci
. 2024 Mar;
45(6):2423-2426.
PMID: 38546935
Fingolimod is approved in Italy as a second-line therapy for relapsing-remitting multiple sclerosis (RRMS). Discontinuation of fingolimod may elevate the risk of relapses, typically manifesting after a relatively prolonged drug-free...
5.
Giovannini B, Bianchi F, Montano V, Siciliano G, Pasquali L
Neurol Sci
. 2024 Feb;
45(5):1845-1848.
PMID: 38315251
No abstract available.
6.
Donatelli G, Cecchi P, Migaleddu G, Cencini M, Frumento P, DAmelio C, et al.
Neuroimage Clin
. 2023 Sep;
40:103509.
PMID: 37717382
Objectives: The disruption of the blood-brain barrier (BBB) is a key and early feature in the pathogenesis of demyelinating multiple sclerosis (MS) lesions and has been neuropathologically demonstrated in both...
7.
Pascazio A, Maestri M, Pasquali L, Hoxhaj D, Fabbrini M, Furfori G, et al.
Mult Scler Relat Disord
. 2023 Aug;
79:104946.
PMID: 37639779
Background: Restless Legs Syndrome is a sleep-related sensorimotor disorder with a higher prevalence in Multiple Sclerosis (MS) patients than in the general population. Our aim was to determine the prevalence...
8.
Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo M, et al.
Eur J Neurol
. 2023 May;
30(8):2357-2364.
PMID: 37154406
Background And Purpose: Although two doses of COVID-19 vaccine elicited a protective humoral response in most persons with multiple sclerosis (pwMS), a significant group of them treated with immunosuppressive disease-modifying...
9.
Canovetti S, Pasquali L, Di Salle G, Lucchi G, Donatelli G, Cosottini M
Radiol Case Rep
. 2022 Sep;
17(11):4132-4134.
PMID: 36097595
Abducens nerve palsy is a common ocular motor paralysis with a broad set of etiopathogenetic causes. Magnetic resonance imaging is a key diagnostic technique to investigate organic causes of sixth...
10.
Schiavetti I, Cordioli C, Stromillo M, Ferro M, Laroni A, Cocco E, et al.
Mult Scler
. 2022 Jun;
28(13):2106-2111.
PMID: 35735030
Background: Patients with multiple sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines. Objective: In this study we aimed to monitor the risk of...